title: Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
abstract: Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
authors.affiliation: Department of Digestive Surgery, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Kermiche-Rahali
authors.forename: Aude
authors.initials: A
authors.lastname: Di Fiore
authors.forename: Fanny
authors.initials: F
authors.lastname: Drieux
authors.forename: Frédéric
authors.initials: F
authors.lastname: Di Fiore
authors.forename: Arnaud
authors.initials: A
authors.lastname: François
authors.forename: Michel
authors.initials: M
authors.lastname: Scotté
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011169:Portal Vein / Q000187:drug effects* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012074:Remission Induction; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: J Clin Oncol. 2011 Apr 20;29(12):e330-2
references.pmid: 21263091
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Ann Surg Oncol. 2013 Oct;20(11):3603-9
references.pmid: 23715965
references.citation: Liver Transpl. 2010 May;16(5):658-67
references.pmid: 20440775
references.citation: J Exp Clin Cancer Res. 2006 Sep;25(3):403-9
references.pmid: 17167981
references.citation: J Natl Cancer Inst. 2008 May 21;100(10):698-711
references.pmid: 18477802
references.citation: Lancet. 2003 Dec 6;362(9399):1907-17
references.pmid: 14667750
references.citation: Ann Surg. 2013 May;257(5):929-37
references.pmid: 23426336
references.citation: Int J Hepatol. 2011;2011:791013
references.pmid: 22135750
references.citation: Liver Int. 2011 May;31(5):740-3
references.pmid: 21457447
references.citation: Abdom Imaging. 2006 Sep-Oct;31(5):537-44
references.pmid: 16865315
references.citation: Hepatology. 2005 Nov;42(5):1208-36
references.pmid: 16250051
references.citation: Hepatology. 2002 Mar;35(3):519-24
references.pmid: 11870363
references.citation: J Hepatol. 2001 Sep;35(3):421-30
references.pmid: 11592607
references.citation: Cancer Res. 2004 Oct 1;64(19):7099-109
references.pmid: 15466206